Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients
NCT04168138Unknown
- Start
- Nov 2019
- Primary completion
- Dec 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label, single-arm trial of recombinant human thrombopoietin in acute myeloid leukemia (AML). Primary endpoint: Progression Free Survival at 2 years. Status: unknown.
02
Drugs
recombinant human thrombopoietin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04168138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04168138.